PBYI
Puma Biotechnology, Inc.NASDAQHealthcare$6.90-0.14%ClosedMarket Cap: $351.0M
As of 2026-04-06
Valuation
P/E (TTM)
11.30
PEG
4.30
P/B
2.66
P/S
1.53
EV/EBITDA
5.92
DCF Value
$17.85
FCF Yield
11.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
74.5%
Operating Margin
16.3%
Net Margin
13.6%
ROE
27.8%
ROA
14.4%
ROIC
20.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $75.5M | 69.3% | $17.1M | $13.4M | $0.26 | — |
| FY 2025 | $228.4M | 74.5% | $37.3M | $31.1M | $0.61 | — |
| Q3 2025 | $54.5M | 77.7% | $9.6M | $8.8M | $0.17 | — |
| Q2 2025 | $52.4M | 76.5% | $6.6M | $5.9M | $0.12 | — |
| Q1 2025 | $46.0M | 77.1% | $4.0M | $3.0M | $0.06 | — |
| Q4 2024 | $59.1M | 76.4% | $13.4M | $19.3M | $0.39 | — |
| FY 2024 | $230.5M | 72.1% | $31.0M | $30.3M | $0.62 | — |
| Q3 2024 | $80.5M | 63.9% | $22.1M | $20.3M | $0.41 | — |
| Q2 2024 | $47.1M | 77.4% | $-2.2M | $-4.5M | $-0.09 | — |
| Q1 2024 | $43.8M | 75.5% | $-2.3M | $-4.8M | $-0.10 | — |
| Q4 2023 | $72.2M | 66.3% | $14.8M | $12.3M | $0.26 | — |
| FY 2023 | $235.6M | 73.4% | $32.6M | $21.6M | $0.45 | — |